Eli Lilly delays preliminary of antibody drug Donald Trump promoted as COVID-19 ‘cure’ over wellbeing concern Kumar Jeetendra | October 14, 2020 Eli Lilly and Co said on Tuesday the clinical trial of its COVID-19 antibody treatment similar to one taken by US President Donald Trump has been paused due to a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as compared to …
Russia prepared to trial combined AstraZeneca, Sputnik V antibody in Ukraine Kumar Jeetendra | January 3, 2021 Russia is ready to run clinical trials in Ukraine of a COVID-19 vaccine combining its Sputnik V with a vaccine developed by AstraZeneca together with Oxford University, the head of Russian Direct Investment Fund (RDIF) said on Saturday. Russia’s autonomous RDIF, which is marketing the Sputnik V vaccine overseas, announced in December trials to test …
FDA-endorsed COVID-19 medication should be utilized warily, says UC researcher Kumar Jeetendra | January 4, 2021 While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics continue to be necessary to treat hepatitis patients. One of these treatments, remdesivir, is the first and only antiviral agent of its type the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19. Research at the University …
Bal Pharma dispatches antiviral drug Favipiravir at Rs 85/tablet Kumar Jeetendra | May 24, 2021 Drug maker Bal Pharma on Monday said it has launched antiviral drug Favipiravir in the domestic market under the brand name BALflu for the treatment of COVID-19. The Bengaluru-based company said its formulation would be available in tablet form with 400 mg strength. Favipiravir is being used for patients with mild to moderate COVID-19 infection as it …
More youngsters contaminated with COVID, no requirement for panic but important to immunize: Experts Kumar Jeetendra | May 25, 2021 More children are testing positive in the second Covid wave but the infection is mostly mild and the mortality rate low, say experts, citing increased testing and enhanced understanding of symptoms as among the possible reasons for the rising graph. Though there is enough anecdotal evidence of COVID-19 catching children – early teens and younger …
British intelligence trusts COVID-19 lab spill hypothesis ‘feasible’: Report Kumar Jeetendra | May 31, 2021 More than 170 million confirmed cases have since been confirmed worldwide and at least 3.5 million deaths reported. British intelligence agencies now believe it is “feasible” that the COVID-19 pandemic began with a coronavirus leak from a Chinese bio laboratory, a media report said, prompting Vaccines Minister Nadhim Zahawi to demand that the WHO must …
AstraZeneca vaccine’s investigator backs India’s 12–16-week Covishield dose gap Kumar Jeetendra | June 19, 2021 Backing the 12-16 weeks gap between the two doses of Covishield in India, the chief investigator of the AstraZeneca vaccine clinical trials on June 18 said that the level of protection provided by one dose of the preventive significantly increases in the second and third months after the jab. In an interview with The Wire, …
AstraZeneca COVID-19 immunization connected to uncommon neurological disorder in India, UK Kumar Jeetendra | June 22, 2021 Eleven people who received the AstraZeneca-Oxford COVID-19 vaccine have developed a rare neurological disorder called Guillain-Barre syndrome, clinicians in India and England have reported in two separate studies. While seven cases were reported from a medical centre in Kerala, where about 1.2 million people were administered the AstraZeneca COVID-19 vaccine, known as Covishield in India, …
BDR Pharma inks permit concurrence with DRDO to deliver COVID-19 drug 2-DG Kumar Jeetendra | July 26, 2021 BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country. BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) …
